Rapid Micro Biosystems to Participate in the Cowen 43rd Annual Health Care Conference

Rhea-AI Summary

Rapid Micro Biosystems (Nasdaq: RPID) announced participation in the Cowen 43rd Annual Health Care Conference in Boston on March 8, 2023. The Company's President and CEO Rob Spignesi, along with CFO Sean Wirtjes, will engage in a 30-minute Q&A session starting at 9:10 a.m. Eastern Time. A live webcast will be available on the Company’s investor relations website and can be replayed for 90 days post-event. Rapid Micro Biosystems specializes in automation solutions for healthcare product manufacturing, enhancing microbial quality control with its Growth Direct System. This innovation supports faster results, greater accuracy, and compliance in the production of biologics and vaccines.

LOWELL, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that the Company will participate in the Cowen 43^rd Annual Health Care Conference in Boston, Massachusetts.

Rob Spignesi, President and CEO, and Sean Wirtjes, CFO, are scheduled to participate in a 30-minute question-and-answer session with the host analyst on Wednesday, March 8, 2023 at 9:10 a.m. Eastern Time. A live webcast of the presentation will be available on the Rapid Micro Biosystems investor relations website at https://investors.rapidmicrobio.com/ and can be accessed here. The webcast will be archived and available for replay for at least 90 days after the event.

About Rapid Micro Biosystems

Rapid Micro Biosystems is an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company’s flagship Growth Direct System automates and modernizes the antiquated, manual microbial quality control (“MQC”) testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct System brings the quality control lab to the manufacturing floor, unlocking the power of MQC automation to deliver the faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making that customers rely on to ensure safe and consistent supply of important healthcare products. The Company is headquartered and has U.S. manufacturing in Lowell, Massachusetts, with global locations in Lexington, Massachusetts, Switzerland, Germany, and the Netherlands. For more information, please visit www.rapidmicrobio.com or follow the Company on Twitter at @rapidmicrobio or on LinkedIn.

FAQ

What is Rapid Micro Biosystems scheduled to present at the Cowen 43rd Annual Health Care Conference?

Rapid Micro Biosystems will participate in a Q&A session on March 8, 2023, at 9:10 a.m. Eastern Time.

Who will represent Rapid Micro Biosystems at the Cowen Conference?

Rob Spignesi (President and CEO) and Sean Wirtjes (CFO) will represent the Company.

Where can I watch the webcast of the Rapid Micro Biosystems presentation?

The live webcast can be accessed on the Company’s investor relations website.

How long will the webcast of the Rapid Micro Biosystems presentation be available?

The webcast will be archived and available for replay for at least 90 days after the event.

What innovations does Rapid Micro Biosystems provide for healthcare manufacturing?

The Company offers the Growth Direct System, automating microbial quality control to enhance efficiency and compliance in manufacturing healthcare products.